09:54 AM EST - ProMetic Life Sciences Inc. : announced today that it has completed relevant milestones regarding the agreement entered into in March 2011 with Celgene Corporation for the worldwide rights to a commercial application of ProMetic's Protein Technologies within a field of use. As a result, a $10.0 million U.S. long-term debt owed to Abraxis BioScience LLC, a wholly-owned subsidiary of Celgene, has been completely and irrevocably forgiven. ProMetic Life Sciences Inc.
shares T.PLI are trading unchanged at $0.15.
